Evidence for an extended interacting surface between β-amyloid and serum amyloid P component

Neuroscience Letters

Volumn 412, Issue 1, 2007, Pages 51-55

  Likó, István ^a   Mák, Marianna ^a   Klement, Éva ^b   Hunyadi Gulyás, Éva ^b   Pázmány, Tamás ^a   Medzihradszky, Katalin F ^b,c   Urbányi, Zoltán ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b INSTITUTE OF BIOCHEMISTRY   (Hungary)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid; Alzheimer's disease; Limited proteolysis; Mass spectrometry; Serum amyloid P component; Structural study

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM ION; GLYCINE; SERUM AMYLOID P; TYROSINE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DEGENERATIVE DISEASE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING;

AMYLOID BETA-PROTEIN; BINDING SITES; GLYCINE; HUMANS; MODELS, MOLECULAR; SERUM AMYLOID P-COMPONENT; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; TYROSINE;

EID: 33845973413     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.10.052     Document Type: Article

References (24)

1. Biemann K. Nomenclature for peptide fragment ions (positive ions). Meth. Enzymol. 193 (1990) 886-887
2. Botto M., Hawkins P.N., Bickerstaff M.C.M., Herbert J., Bygrave A.E., McBride A., Hutchinson W.L., Tennent G.A., Walport M.J., and Pepys M.B. Amyloid deposition is delayed in mice with targeted deletion of serum amyloid P component gene. Nat. Med. 3 (1997) 855-859
3. Coker A.R., Purvis A., Baker D., Pepys M.B., and Wood S.P. Molecular chaperon properties of serum amyloid P component. FEBS Lett. 473 (2000) 199-202
4. Emsley J., White H.E., O'Hara B.P., Oliva G., Srinivasan N., Tickle I.J., Blundell T.L., Pepys M.B., and Wood S.P. Structure of pentameric human serum amyloid P component. Nature 367 (1994) 338-345
5. Guex N., and Peitsch M.C. SWISS-MODEL. The Swiss-PdbViewer: an environment for comparative protein modelling. Electrophoresis 18 (1997) 2714-2723
6. Gupta-Bansal R., and Brunden K.R. Congo Red inhibits proteoglycan and serum amyloid P binding to amyloid fibrils. J. Neurochem. 70 (1998) 292-298
7. 2+-dependent binding of human serum amyloid P component to Alzheimer's β-amyloid peptide. J. Biol. Chem. 270 (1995) 10392-10394
8. Hawkins P.N., Rossor M.N., Gallimore J.R., Miller B., Moore E.G., and Pepys M.B. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem. Biophys. Res. Commun. 201 (1994) 722-726
9. Inoue S., Kuroiwa M., and Kisilevsky R. Basement membranes, microfibrils and β amyloid fibrillogenesis in Alzheimer's disease: high resolution ultrastructural findings. Brain Res. Rev. 29 (1999) 218-231
10. Jager P.L., Hazenberg B.P.C., Franssen E.J.F., Limburg P.C., van Rijswijk M.H., and Piers D.A. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J. Nucl. Med. 39 (1998) 699-706
11. Kalaria R.N., Galloway P.G., and Perry G. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol. Appl. Neurobiol. 17 (1991) 189-201
12. Kalaria R.N., and Grahovac I. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implication for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res. 516 (1990) 349-353
13. 2+-binding region of human serum amyloid P component and other pentraxins. Prot. Sci. 1 (1992) 700-709
14. Müller-Hill B., and Beyreuther K. Molecular biology of Alzheimer's disease. Annu. Rev. Biochem. 58 (1989) 287-307
15. Nybo M., Olsen H., Jeune B., Andersen-Ranberg K., Nielsen E.H., and Svehag S.-E. Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement. Geriatr. Cogn. Disord. 9 (1998) 126-129
16. Pepys M.B. Serum amyloid P component. Structure, function and role in amyloidosis. In: Kyle R.A., and Gertz M.A. (Eds). Amyloid and amyloidosis (1999), The Parthenon Publishing Group, Pearl River, NY 6-10
17. Pepys M.B., Booth D.R., Hutchinson W.L., Gallimore J.R., Collins P.M., and Hohenester E. Amyloid P component. A critical review. Amyloid: Int. J. Exp. Clin. Invest. 4 (1997) 274-295
18. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C., Hoffmann T., Jakob-Roetne R., Norcross R.D., Kemp J.A., Yamamura K., Suzuki M., Taylor G.W., Murray S., Thompson D., Purvis A., Kolstoe S., Wood S.P., and Hawkins P.N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417 (2002) 254-259
19. Perlmutter L.S., Barrón E., Myers M., Saperia D., and Chui H.C. Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer's disease lesions. J. Comp. Neurol. 352 (1995) 92-105
20. Shi J., Perry G., Berridge M.S., Aliev G., Siedlak S.L., Smith M.A., LaManna J.C., and Friedland R.P. Labeling of cerebral amiloid β deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J. Nucl. Med. 43 (2002) 1044-1051
21. Skinner M., and Cohen A.S. Amyloid P component. Methods Enzymol. 163 (1988) 523-536
22. Tennent G.A., Lovat L.B., and Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Nat. Acad. Sci. U.S.A. 92 (1995) 4299-4303
23. Urbányi Z., László L., Tomasi T.B., Tóth E., Mekes E., Sass M., and Pázmány T. Serum amyloid P component induces neuronal apoptosis and β-amyloid immunoreactivity. Brain Res. 988 (2003) 69-77
24. Urbányi Z., Forrai E., Sárvári M., Likó I., Illés J., and Pázmány T. Glycosaminoglycans inhibit neurodegenerative effects of serum amyloid P component in vitro. Neurochem. Int. 46 (2005) 471-477